PERSISTENT FILMY PREPARATION FOR TOPICAL ADMINISTRATION CONTAINING PROSTAGLANDIN DERIVATIVE

Details for Australian Patent Application No. 2002318760 (hide)

Owner ONO PHARMACEUTICAL CO., LTD.

Inventors TABATA, Yasuhiko; NISHIURA, Akio

Pub. Number AU-A-2002318760

PCT Number PCT/JP02/07386

PCT Pub. Number WO2003/041717

Priority 2001-345678 12.11.01 JP

Filing date 22 July 2002

Wipo publication date 26 May 2003

International Classifications

A61K 031/5575

A61K 009/70 Medicinal preparations characterised by special physical form - Web, sheet or filament bases

A61P 001/02 Drugs for disorders of the alimentary tract or the digestive system

A61P 003/14 Drugs for disorders of the metabolism

A61P 019/00 Drugs for skeletal disorders

A61P 019/02 Drugs for skeletal disorders

A61P 019/08 Drugs for skeletal disorders

A61P 019/10 Drugs for skeletal disorders

A61P 035/04 Antineoplastic agents

Event Publications

9 January 2003 Complete Application Filed

  Priority application(s): 2001-345678 12.11.01 JP

24 July 2003 Application Open to Public Inspection

  Published as AU-A-2002318760

29 July 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002318761-NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTIC SOLUTION SECONDARY CELL USING THE SAME

2002318759-Remedies for diseases with bone mass loss having EP4 agonists as the active ingredient